胸腺融合肽Tα1-TP5的表达、纯化和活性研究
|
摘要
胸腺五肽(thymopentin,TP5)是位于胸腺生成素Ⅱ的第32～36位氨基酸残基片段,具有与TPⅡ相似的生物学活性,能双向调节失衡的免疫系统。TP5能诱导T细胞的分化,促进T淋巴细胞亚群发育并活化,是一种重要的免疫调节剂,临床上主要用于免疫缺陷症和自身免疫性疾病的治疗。因TP5半衰期较短(30 s),人们制备了许多TP5的类似物或模拟肽来延长TP5的半衰期并提高其活性,如在TP5之间插入稳定性成分、用D-型氨基酸取代L-型氨基酸,或者制成环肽等,尽管这些工作取得了一定的成绩,但结果却难以令人满意。
Tα1是一种天然存在于多种生物组织的多肽物质,由28个氨基酸残基组成,等电点4.2,分子量3108 Da。Tα1具有与TP5类似的免疫活性,主要是增强细胞免疫,用于免疫缺陷或免疫功能低下相关的疾病。Tα1的血浆半衰期约1.5 h。目前,Tα1主要从动物组织中提取或化学合成,但从组织中提取存在产量低、产物不稳定等缺点,而化学合成则价格昂贵。
为了提高TP5的活性,延长其半衰期,本研究依据肽链延长可提高多肽类药物体内半衰期的事实,将具有相似生物活性与临床用途的TP5和Tα1借助基因工程方法连接在了一起,表达制备了Tα1-TP5融合肽。
1 Tα1-TP5融合肽的基因克隆及在毕赤酵母中的表达
本研究根据Tα1-TP5的氨基酸序列,选用毕赤酵母偏爱的密码子,人工设计合成了Tα1-TP5全基因序列;借助Primer软件,设计了上下游引物,通过PCR反应、酶切、连接等步骤,构建了融合基因Tα1-TP5表达载体pGAPZαA-Tα1-TP5。
由于在毕赤酵母中表达融合肽可能出现N-端和C-端不均一的现象,在构建表达载体时时采取了两种方法:第一,将目的基因直接插在α-信号肽后面的Glu-Ala-Glu-Ala处;第二,在目的基因C-端增加了凝血酶酶切位点的编码基因,保留了6×His纯化标签。这样,既能简便快捷的用金属鳌合亲和填料纯化表达产物,又能通过凝血酶高效完全地切除N-端多余氨基酸残基和6×His标签,得到Tα1-TP5融合肽,从而提高Tα1-TP5融合肽的纯化效率。
采用电激法用BlnⅠ线性化载体pGAPZαA-Tα1-TP5转化P.pastoris GS115,筛选Zeocine高抗性的阳性克隆,用煮-冻-煮法提取酵母基因组DNA,用PCR方法对P.pastoris GS115的基因表型进行了鉴定。重组转化子经摇瓶培养,Tricine-SDS-PAGE证明上清液中含有Tα1-TP5融合肽,其中两个转化子表达量较高。考查了发酵时间、培养温度对Tα1-TP5融合肽表达量的影响。结果显示,在30℃、72 h后发酵上清中的Tα1-TP5表达量最高,达32.2 mg/L。
2 Tα1-TP5融合肽的分离纯化
研究了Tα1-TP5融合肽的分离纯化工艺。发酵混合物经高速离心取上清,用超滤法去除大分子的蛋白酶、金属螯和层析纯化融合肽、冷冻干燥浓缩、SephadexG-25凝胶过滤脱盐、凝血酶酶切后用SephadexG-70凝胶过滤分离,再干燥浓缩,目的产物Tα1-TP5融合肽在Tricine-SDS-PAGE上呈现单一条带。ESI-MS也证实了Tα1-TP5融合肽在毕赤酵母中得到正确的分泌表达。
3 Tα1-TP5融合肽的二级结构研究
利用圆二色谱(Circular Dichroism,CD)与傅立叶变换红外光谱(fouriertransform infrared spectroscopy,FTIR)对Tα1-TP5融合肽的二级结构进行了分析。CD结果显示Tα1-TP5融合肽中二级结构的各构象分别是α-helix为32.01%,β-antiparallel为8.50%,β-parallel为8.86%,β-turn为17.02%,random coil为33.61%,说明Tα1-TP5融合肽分子结构中,α-helix和random coil是二级结构的主要部分。该结果FTIR的分析结果基本一致,二种分析方法相互补充,相互印证。
4 Tα1-TP5融合肽体外半衰期的研究
从家兔心脏取血后进行肝素抗凝,加入一定浓度的多肽药物,37℃水浴,于不同的时间点取样,用盐酸丙酮(盐酸:丙酮:水=1:40:5,v/v)对血浆样品进行处理,高速离心得到沉淀,用醋酸溶解。用RP-HPLC测定不同保温时间血浆中Tα1-TP5、Tα1及TP5的浓度,计算Tα1-TP5、Tα1及TP5体外血浆半衰期。结果表明,Tα1-TP5、Tα1及TP5的血浆半衰期分别为140±14 min、127±11 min和5.6±0.7 min。Tα1-TP5融合肽较TP5的体外血浆半衰期有明显差异(p＜0.01)。
5 Tα1-TP5融合肽的活性研究
小鼠脾细胞增殖实验表明,在系列浓度为10~(-11)～10~(-6)mol/L时,Tα1-TP5融合肽对昆明小鼠脾淋巴细胞的的最大增殖率为50.97±5.19%,Tα1的最大增殖率为45.38±8.26%,TP5融合肽的最大增殖率为40.61±5.17%,Tα1-TP5融合肽与TP5之间有显著性差异(p＜0.01)。
在巨噬细胞的吞噬实验中,Tα1-TP5融合肽组、Tα1组、TP5组和对照组的廓清指数K分别为0.020±0.0010、0.016±0.0007、0.013±0.0008和0.005±0.0006,而对应的吞噬指数依次为3.95±0.19、3.73±0.56、3.43±0.29和2.48±0.40。结果表明,各药物组均能影响正常小鼠单核巨噬细胞吞噬功能,且融合肽的廓清指数K和吞噬指数α也显著高于其它组(P＜0.01)。
通过研究Tα1-TP5、Tα1和TP5对小鼠血清中IL-2的表达的影响表明,Tα1-TP5融合肽组的平均水平为848.81±46.70 pg/mL,Tα1组的平均水平为761.50±31.33 pg╱mL,而TP5组的平均水平为749.62±29.08 pg/mL,对照组为718.35±32.16 pg/mL,融合肽较其它实验组有显著性差异(P＜0.01)。这表明Tα1-TP5融合肽较Tα1和TP5能更有效地促进淋巴细胞分泌IL-2。
考虑到Tα1-TP5融合肽的结构与功能的关系,认为Tα1-TP5融合肽免疫活性的提高是由于Tα1-TP5构象的微小变化,尤其是α-helix含量的升高引起的。因为α-helix被认为是Tα1的主要活性中心,α-helix含量的升高,不仅显著延长了Tα1-TP5融合肽的半衰期,而且Tα1-TP5融合肽与靶细胞的持久作用更有利于免疫活性的增强。
本实验结果表明,Tα1-TP5融合肽具有潜在的临床应用价值。
本研究取得的主要成果有:
(1)构建了pGAPZαA-Tα1-TP5表达载体,并采用毕赤酵母表达系统对Tα1-TP5融合肽进行了分泌表达,表达量可达32.2 mg/L,用ESI-MS证实了其结构的正确性。
(2)建立了实验室水平的Tα1-TP5融合肽分离纯化工艺,经过超滤、亲和层析和凝胶过滤三步骤,所获得产品的纯度可达到99%以上。
(3)用CD和FTIR研究了Tα1-TP5融合肽的二级结构,表明α-helix和random coil是其二级结构的主要组成部分。推测Tα1-TP5融合肽二级结构中的α-helix构象是影响其活性的重要因素。
(4)与TP5和Tα1相比较进行了Tα1-TP5融合肽体外血浆t_(1╱2)研究,显示Tα1-TP5融合肽的半衰期约为140±14 min,高于同比试验TP5(5.6±0.7 min)和Tα1(127±11min)。
(5)进行了胸腺Tα1-TP5融合肽体内外免疫活性研究,表明融合肽Tα1-TP5在促进昆明小鼠脾细胞的增殖、增加巨噬细胞的吞噬功能,和促进IL-2表达的实验中均显示了比TP5和Tα1更高的活性,是一个活性较好的潜在的免疫调节药物。
本研究为一种新型免疫调节剂的开发奠定了基础。
Thymopentin(TP5),corresponding to the position 32-36 of thymopoietin,which exhibits similarly biological activities as thymopoietin,can have a function of two-ways regulation on imbalanced immune system.As an important immunomodulator,TP5 can induce T cell differentiation and promote the development and activation of T-lymphocyte subsets,resulting in curing immune deficiency and autoimmune disorders in clinical application.Because its half-life is very short(30 s),many TP5 analogs and peptidomimetics such as the insertion of stable components,D-amino acid substitution or cyclic peptide,have been prepared to enhance their half-lives and activities.However,all the results were still not satisfactory.
Thymosonα1(Tα1),a natural polypeptide existing in a variety of biological tissues,is composed of 28 amino acid residues with a molecular weight of 3100 Da, pI 4.2,and has similar immunocompetence as TP5.As an immunomodulator,Tα1 has been used clinically for the treatment of immune defects.Plasm half-life of Tα1 was about 1.5 h.Currently,Tα1 is prepared from the animal tissues or chemical synthesis, so it has many shortcomings,e.g.low yields,and high price.
Based on the facts that the proper extension of peptide chain can improve half-lives of peptide drugs,to elongate the half-life and activity of TP5,Tα1 was fused with TP5 and Tα1-TP5 fusion peptide was prepared by genetic engineering.
1 Cloning and expression of Tα1-TP5 gene in P.pastoris
In this dissertation,a synthetic gene encoding a Tα1-TP5 was synthesized on the basis of its amino acid sequence and P.pastoris preferred codons.Upstream and downstream primers were designed by primer software,and then Tα1-TP5 gene was manipulated by PCR amplification,restriction enzyme digestion and ligation,and cloned into the P.pastoris expression vector pGAPZαA.The recombinant plasmid pGAPZαA-Tα1-TP5 was transformed into E.coli JM109,and then colony screening, restriction enzyme digestion,PCR reaction and sequence analysis showed that the synthesized gene and cloned gene were consistent completely with designed gene.
There are some cases where unnecessary amino acids are left on the N- and C-terminus of the expressed fusion peptide.In our study,we inserted target gene rightly behind the Glu-Ala-Glu-Ala ofα-factor signal sequence,added a thrombin site gene between the C-terminus and stop condon,remaining 6×his tag.In this way, fusion peptide could be easily purified by metal chelating affinity chromatography, and the purified products could be further cleaved by thrombin to obtain Tα1-TP5 fusion peptide.
BlnⅠ-lineared pGAPZαA-Tα1-TP5 was transformed into P.pastoris GS115 strain and positive colonies were screened with high concentration of Zeocin.Yeast genomic DNA was extracted by boiling-freezing-boiling and identified by PCR amplification.The recombinant transformants were cultured in the shake flask. Tricine-SDS-PAGE showed the production of Tα1-TP5 and found two transformants had high yields.The influence of culture time and temperature were studied.When cultured at 30℃to optical density at 72 h,the recombinant Tα1-TP5 fusion peptide reached 32.2 mg/L.
2 Separation and purification of Tα1-TP5 fusion peptide
The technology of separation and purification of the fusion peptide was studied. After gaining the supematant by centrifugation,the macromolecules including proteases were removed by ultrafiltration,the fusion peptide was separated by metal chelate chromatography,and desalted and purified by G-25 gel filtration.Fusion peptide was digested by thrombin and was concentrated again.The purified Tα1-TP5 fusion peptide sample showed a single band by Tricine-SDS-PAGE.The correct molecular weight of Tα1-TP5 was further confirmed with ESI-MS.
3 The secondary structure study of Tα1-TP5 fusion peptide
The secondary structure of Tα1-TP5 fusion peptide was determined by circular dichroism(CD) spectroscopy and Fourier transform infrared(FTIR) spectroscopy. The CD results showed that the secondary structure of Tα1-TP5 fusion peptide constituted of 32.01%α-helix,8.50%β-antiparallel,8.86%β-parallel,17.02%β-tum, and 33.61%random coil.Theα-helix and random coil covered the most part of the Tα1-TP5 fusion peptide,which was consistent with tendency of the Fourier transform infrared(FTIR) spectroscopy.
4 In vitro plasma half life of Tα1-TP5 fusion peptide
The in vitro plasma half-life of each target peptide was determined by reversed-phase high-performance liquid chromatography(RP-HPLC) following incubation at 37℃in heparinized rabbit plasma at different time points.The results showed that the in vitro half-life of Tα1-TP5 fusion peptide,Tα1 and TP5 were (140±14) min,(127±11) min and(5.6±0.7) min respectively.The half-life of Tα1-TP5 fusion peptide is obviously longer than that of TP5 and Tα1 alone.
5 Activities of Tα1-TP5 fusion peptide
Mouse spleen cell proliferation experiment showed that when the concentration was in the range of 10~(-11) to 10~(-6)mol/L,the largest proliferation ratio of Tα1-TP5,Tα1 and TP5 were(50.97±5.19)%,(45.38±8.257)%and(40.61±5.17)%respectively. Tα1-TP5 has significantly higher activity(P＜0.01) than TP5 in promoting the proliferation of mouse splenocytes in vitro,but the activity difference between Tα1-TP5 and Tα1 was not significant.
The in vivo macrophage phagocytosis experiments showed that the clearance index K of Tα1-TP5 fusion peptide,Tα1,TP5 and control were 0.020±0.0010, 0.016±0.0007,0.013±0.0008 and 0.005±0.0006 respectively.And their phagocytic index corresponded 3.95±0.19,3.73±0.56,3.43±0.29 and 2.48±0.40.All the peptide drugs could enhance the normal mouse macrophage phagocytosis,and Tα1-TP5 had better activity in promoting the phagocytosis of macrophages than TP5.
The quantitative analysis of IL-2 in the serum of the peptide drug treated mice showed that the average IL-2 level of Tα1-TP5,Tα1,TP5 and control group were 848.81±46.70 pg/mL,761.50±31.33 pg/mL,749.62±29.08 pg/mL and 718.35±32.16 pg/mL respectively.These demonstrated that Tα1-TP5 fusion peptide has significantly higher activity in promoting T lymphocytes to secrete IL-2 than Tα1 or TP5 alone does.
In view of the relations betweem structure and function of Tα1-TP5,enhanced activity may attribute to the small conformational changes of Tα1-TP5,compared with Tα1,especially the small increase ofα-helix structure,because in previous studies,it was presumed thatα-helix structure played a main role in the activity of Tα1.
In summary,this study showed Tα1-TP5 might be used as a potential therapeutic agent for the human aliments.
In this study,the main research results are as follows:
(1) The vector pGAPZαA-Tα1-TP5 was constructed.Tα1-TP5 fusion peptide was expressed in P.pastoris and its expression level was detected to be 32.2 mg/L in the culture.ESI-MS confirmed its correctness of its structure.
(2) A method of separation and purification of Tα1-TP5 fusion peptide in laboratory level was establishe.Tα1-TP5 fusion peptide was well purified by a serial of ultrafiltration,affinity adsorbtion and gel filtration and the purity of the product was over 99%.
(3) The secondary structure of Tα1-TP5 was studied by CD spectroscopy and FTIR pectroscopy.Theα-helix and random coil covered the most part of its secondary structure.Further speculated theα-helix conformation was an important factor for its immunocompetence.
(4) The in vitro plasma half-life of Tα1-TP5 was studied,and the results conformed that its half-life(140±14 min) is significantly longer than that of TP5 (5.6±0.7 min) or Tα1(127±11min).
(5) The in vitro activity assay presented that Tα1-TP5 fusion peptide has greater activity in promoting proliferation of Kunming mouse splenocytes,and in vivo experiment showed that Tα1-TP5 fusion peptide had better activity in promoting the phagocytosis of macrophages and secretion of IL-2 than both Tα1 and TP5.Our findings suggested that Tα1-TP5 fusion peptide might be a potential therapeutic agent.
In a word,this study has provided a basis for the further medicinal development of Tα1-TP5 fusion peptide.
Tα1是一种天然存在于多种生物组织的多肽物质,由28个氨基酸残基组成,等电点4.2,分子量3108 Da。Tα1具有与TP5类似的免疫活性,主要是增强细胞免疫,用于免疫缺陷或免疫功能低下相关的疾病。Tα1的血浆半衰期约1.5 h。目前,Tα1主要从动物组织中提取或化学合成,但从组织中提取存在产量低、产物不稳定等缺点,而化学合成则价格昂贵。
为了提高TP5的活性,延长其半衰期,本研究依据肽链延长可提高多肽类药物体内半衰期的事实,将具有相似生物活性与临床用途的TP5和Tα1借助基因工程方法连接在了一起,表达制备了Tα1-TP5融合肽。
1 Tα1-TP5融合肽的基因克隆及在毕赤酵母中的表达
本研究根据Tα1-TP5的氨基酸序列,选用毕赤酵母偏爱的密码子,人工设计合成了Tα1-TP5全基因序列;借助Primer软件,设计了上下游引物,通过PCR反应、酶切、连接等步骤,构建了融合基因Tα1-TP5表达载体pGAPZαA-Tα1-TP5。
由于在毕赤酵母中表达融合肽可能出现N-端和C-端不均一的现象,在构建表达载体时时采取了两种方法:第一,将目的基因直接插在α-信号肽后面的Glu-Ala-Glu-Ala处;第二,在目的基因C-端增加了凝血酶酶切位点的编码基因,保留了6×His纯化标签。这样,既能简便快捷的用金属鳌合亲和填料纯化表达产物,又能通过凝血酶高效完全地切除N-端多余氨基酸残基和6×His标签,得到Tα1-TP5融合肽,从而提高Tα1-TP5融合肽的纯化效率。
采用电激法用BlnⅠ线性化载体pGAPZαA-Tα1-TP5转化P.pastoris GS115,筛选Zeocine高抗性的阳性克隆,用煮-冻-煮法提取酵母基因组DNA,用PCR方法对P.pastoris GS115的基因表型进行了鉴定。重组转化子经摇瓶培养,Tricine-SDS-PAGE证明上清液中含有Tα1-TP5融合肽,其中两个转化子表达量较高。考查了发酵时间、培养温度对Tα1-TP5融合肽表达量的影响。结果显示,在30℃、72 h后发酵上清中的Tα1-TP5表达量最高,达32.2 mg/L。
2 Tα1-TP5融合肽的分离纯化
研究了Tα1-TP5融合肽的分离纯化工艺。发酵混合物经高速离心取上清,用超滤法去除大分子的蛋白酶、金属螯和层析纯化融合肽、冷冻干燥浓缩、SephadexG-25凝胶过滤脱盐、凝血酶酶切后用SephadexG-70凝胶过滤分离,再干燥浓缩,目的产物Tα1-TP5融合肽在Tricine-SDS-PAGE上呈现单一条带。ESI-MS也证实了Tα1-TP5融合肽在毕赤酵母中得到正确的分泌表达。
3 Tα1-TP5融合肽的二级结构研究
利用圆二色谱(Circular Dichroism,CD)与傅立叶变换红外光谱(fouriertransform infrared spectroscopy,FTIR)对Tα1-TP5融合肽的二级结构进行了分析。CD结果显示Tα1-TP5融合肽中二级结构的各构象分别是α-helix为32.01%,β-antiparallel为8.50%,β-parallel为8.86%,β-turn为17.02%,random coil为33.61%,说明Tα1-TP5融合肽分子结构中,α-helix和random coil是二级结构的主要部分。该结果FTIR的分析结果基本一致,二种分析方法相互补充,相互印证。
4 Tα1-TP5融合肽体外半衰期的研究
从家兔心脏取血后进行肝素抗凝,加入一定浓度的多肽药物,37℃水浴,于不同的时间点取样,用盐酸丙酮(盐酸:丙酮:水=1:40:5,v/v)对血浆样品进行处理,高速离心得到沉淀,用醋酸溶解。用RP-HPLC测定不同保温时间血浆中Tα1-TP5、Tα1及TP5的浓度,计算Tα1-TP5、Tα1及TP5体外血浆半衰期。结果表明,Tα1-TP5、Tα1及TP5的血浆半衰期分别为140±14 min、127±11 min和5.6±0.7 min。Tα1-TP5融合肽较TP5的体外血浆半衰期有明显差异(p＜0.01)。
5 Tα1-TP5融合肽的活性研究
小鼠脾细胞增殖实验表明,在系列浓度为10~(-11)～10~(-6)mol/L时,Tα1-TP5融合肽对昆明小鼠脾淋巴细胞的的最大增殖率为50.97±5.19%,Tα1的最大增殖率为45.38±8.26%,TP5融合肽的最大增殖率为40.61±5.17%,Tα1-TP5融合肽与TP5之间有显著性差异(p＜0.01)。
在巨噬细胞的吞噬实验中,Tα1-TP5融合肽组、Tα1组、TP5组和对照组的廓清指数K分别为0.020±0.0010、0.016±0.0007、0.013±0.0008和0.005±0.0006,而对应的吞噬指数依次为3.95±0.19、3.73±0.56、3.43±0.29和2.48±0.40。结果表明,各药物组均能影响正常小鼠单核巨噬细胞吞噬功能,且融合肽的廓清指数K和吞噬指数α也显著高于其它组(P＜0.01)。
通过研究Tα1-TP5、Tα1和TP5对小鼠血清中IL-2的表达的影响表明,Tα1-TP5融合肽组的平均水平为848.81±46.70 pg/mL,Tα1组的平均水平为761.50±31.33 pg╱mL,而TP5组的平均水平为749.62±29.08 pg/mL,对照组为718.35±32.16 pg/mL,融合肽较其它实验组有显著性差异(P＜0.01)。这表明Tα1-TP5融合肽较Tα1和TP5能更有效地促进淋巴细胞分泌IL-2。
考虑到Tα1-TP5融合肽的结构与功能的关系,认为Tα1-TP5融合肽免疫活性的提高是由于Tα1-TP5构象的微小变化,尤其是α-helix含量的升高引起的。因为α-helix被认为是Tα1的主要活性中心,α-helix含量的升高,不仅显著延长了Tα1-TP5融合肽的半衰期,而且Tα1-TP5融合肽与靶细胞的持久作用更有利于免疫活性的增强。
本实验结果表明,Tα1-TP5融合肽具有潜在的临床应用价值。
本研究取得的主要成果有:
(1)构建了pGAPZαA-Tα1-TP5表达载体,并采用毕赤酵母表达系统对Tα1-TP5融合肽进行了分泌表达,表达量可达32.2 mg/L,用ESI-MS证实了其结构的正确性。
(2)建立了实验室水平的Tα1-TP5融合肽分离纯化工艺,经过超滤、亲和层析和凝胶过滤三步骤,所获得产品的纯度可达到99%以上。
(3)用CD和FTIR研究了Tα1-TP5融合肽的二级结构,表明α-helix和random coil是其二级结构的主要组成部分。推测Tα1-TP5融合肽二级结构中的α-helix构象是影响其活性的重要因素。
(4)与TP5和Tα1相比较进行了Tα1-TP5融合肽体外血浆t_(1╱2)研究,显示Tα1-TP5融合肽的半衰期约为140±14 min,高于同比试验TP5(5.6±0.7 min)和Tα1(127±11min)。
(5)进行了胸腺Tα1-TP5融合肽体内外免疫活性研究,表明融合肽Tα1-TP5在促进昆明小鼠脾细胞的增殖、增加巨噬细胞的吞噬功能,和促进IL-2表达的实验中均显示了比TP5和Tα1更高的活性,是一个活性较好的潜在的免疫调节药物。
本研究为一种新型免疫调节剂的开发奠定了基础。
Thymopentin(TP5),corresponding to the position 32-36 of thymopoietin,which exhibits similarly biological activities as thymopoietin,can have a function of two-ways regulation on imbalanced immune system.As an important immunomodulator,TP5 can induce T cell differentiation and promote the development and activation of T-lymphocyte subsets,resulting in curing immune deficiency and autoimmune disorders in clinical application.Because its half-life is very short(30 s),many TP5 analogs and peptidomimetics such as the insertion of stable components,D-amino acid substitution or cyclic peptide,have been prepared to enhance their half-lives and activities.However,all the results were still not satisfactory.
Thymosonα1(Tα1),a natural polypeptide existing in a variety of biological tissues,is composed of 28 amino acid residues with a molecular weight of 3100 Da, pI 4.2,and has similar immunocompetence as TP5.As an immunomodulator,Tα1 has been used clinically for the treatment of immune defects.Plasm half-life of Tα1 was about 1.5 h.Currently,Tα1 is prepared from the animal tissues or chemical synthesis, so it has many shortcomings,e.g.low yields,and high price.
Based on the facts that the proper extension of peptide chain can improve half-lives of peptide drugs,to elongate the half-life and activity of TP5,Tα1 was fused with TP5 and Tα1-TP5 fusion peptide was prepared by genetic engineering.
1 Cloning and expression of Tα1-TP5 gene in P.pastoris
In this dissertation,a synthetic gene encoding a Tα1-TP5 was synthesized on the basis of its amino acid sequence and P.pastoris preferred codons.Upstream and downstream primers were designed by primer software,and then Tα1-TP5 gene was manipulated by PCR amplification,restriction enzyme digestion and ligation,and cloned into the P.pastoris expression vector pGAPZαA.The recombinant plasmid pGAPZαA-Tα1-TP5 was transformed into E.coli JM109,and then colony screening, restriction enzyme digestion,PCR reaction and sequence analysis showed that the synthesized gene and cloned gene were consistent completely with designed gene.
There are some cases where unnecessary amino acids are left on the N- and C-terminus of the expressed fusion peptide.In our study,we inserted target gene rightly behind the Glu-Ala-Glu-Ala ofα-factor signal sequence,added a thrombin site gene between the C-terminus and stop condon,remaining 6×his tag.In this way, fusion peptide could be easily purified by metal chelating affinity chromatography, and the purified products could be further cleaved by thrombin to obtain Tα1-TP5 fusion peptide.
BlnⅠ-lineared pGAPZαA-Tα1-TP5 was transformed into P.pastoris GS115 strain and positive colonies were screened with high concentration of Zeocin.Yeast genomic DNA was extracted by boiling-freezing-boiling and identified by PCR amplification.The recombinant transformants were cultured in the shake flask. Tricine-SDS-PAGE showed the production of Tα1-TP5 and found two transformants had high yields.The influence of culture time and temperature were studied.When cultured at 30℃to optical density at 72 h,the recombinant Tα1-TP5 fusion peptide reached 32.2 mg/L.
2 Separation and purification of Tα1-TP5 fusion peptide
The technology of separation and purification of the fusion peptide was studied. After gaining the supematant by centrifugation,the macromolecules including proteases were removed by ultrafiltration,the fusion peptide was separated by metal chelate chromatography,and desalted and purified by G-25 gel filtration.Fusion peptide was digested by thrombin and was concentrated again.The purified Tα1-TP5 fusion peptide sample showed a single band by Tricine-SDS-PAGE.The correct molecular weight of Tα1-TP5 was further confirmed with ESI-MS.
3 The secondary structure study of Tα1-TP5 fusion peptide
The secondary structure of Tα1-TP5 fusion peptide was determined by circular dichroism(CD) spectroscopy and Fourier transform infrared(FTIR) spectroscopy. The CD results showed that the secondary structure of Tα1-TP5 fusion peptide constituted of 32.01%α-helix,8.50%β-antiparallel,8.86%β-parallel,17.02%β-tum, and 33.61%random coil.Theα-helix and random coil covered the most part of the Tα1-TP5 fusion peptide,which was consistent with tendency of the Fourier transform infrared(FTIR) spectroscopy.
4 In vitro plasma half life of Tα1-TP5 fusion peptide
The in vitro plasma half-life of each target peptide was determined by reversed-phase high-performance liquid chromatography(RP-HPLC) following incubation at 37℃in heparinized rabbit plasma at different time points.The results showed that the in vitro half-life of Tα1-TP5 fusion peptide,Tα1 and TP5 were (140±14) min,(127±11) min and(5.6±0.7) min respectively.The half-life of Tα1-TP5 fusion peptide is obviously longer than that of TP5 and Tα1 alone.
5 Activities of Tα1-TP5 fusion peptide
Mouse spleen cell proliferation experiment showed that when the concentration was in the range of 10~(-11) to 10~(-6)mol/L,the largest proliferation ratio of Tα1-TP5,Tα1 and TP5 were(50.97±5.19)%,(45.38±8.257)%and(40.61±5.17)%respectively. Tα1-TP5 has significantly higher activity(P＜0.01) than TP5 in promoting the proliferation of mouse splenocytes in vitro,but the activity difference between Tα1-TP5 and Tα1 was not significant.
The in vivo macrophage phagocytosis experiments showed that the clearance index K of Tα1-TP5 fusion peptide,Tα1,TP5 and control were 0.020±0.0010, 0.016±0.0007,0.013±0.0008 and 0.005±0.0006 respectively.And their phagocytic index corresponded 3.95±0.19,3.73±0.56,3.43±0.29 and 2.48±0.40.All the peptide drugs could enhance the normal mouse macrophage phagocytosis,and Tα1-TP5 had better activity in promoting the phagocytosis of macrophages than TP5.
The quantitative analysis of IL-2 in the serum of the peptide drug treated mice showed that the average IL-2 level of Tα1-TP5,Tα1,TP5 and control group were 848.81±46.70 pg/mL,761.50±31.33 pg/mL,749.62±29.08 pg/mL and 718.35±32.16 pg/mL respectively.These demonstrated that Tα1-TP5 fusion peptide has significantly higher activity in promoting T lymphocytes to secrete IL-2 than Tα1 or TP5 alone does.
In view of the relations betweem structure and function of Tα1-TP5,enhanced activity may attribute to the small conformational changes of Tα1-TP5,compared with Tα1,especially the small increase ofα-helix structure,because in previous studies,it was presumed thatα-helix structure played a main role in the activity of Tα1.
In summary,this study showed Tα1-TP5 might be used as a potential therapeutic agent for the human aliments.
In this study,the main research results are as follows:
(1) The vector pGAPZαA-Tα1-TP5 was constructed.Tα1-TP5 fusion peptide was expressed in P.pastoris and its expression level was detected to be 32.2 mg/L in the culture.ESI-MS confirmed its correctness of its structure.
(2) A method of separation and purification of Tα1-TP5 fusion peptide in laboratory level was establishe.Tα1-TP5 fusion peptide was well purified by a serial of ultrafiltration,affinity adsorbtion and gel filtration and the purity of the product was over 99%.
(3) The secondary structure of Tα1-TP5 was studied by CD spectroscopy and FTIR pectroscopy.Theα-helix and random coil covered the most part of its secondary structure.Further speculated theα-helix conformation was an important factor for its immunocompetence.
(4) The in vitro plasma half-life of Tα1-TP5 was studied,and the results conformed that its half-life(140±14 min) is significantly longer than that of TP5 (5.6±0.7 min) or Tα1(127±11min).
(5) The in vitro activity assay presented that Tα1-TP5 fusion peptide has greater activity in promoting proliferation of Kunming mouse splenocytes,and in vivo experiment showed that Tα1-TP5 fusion peptide had better activity in promoting the phagocytosis of macrophages and secretion of IL-2 than both Tα1 and TP5.Our findings suggested that Tα1-TP5 fusion peptide might be a potential therapeutic agent.
In a word,this study has provided a basis for the further medicinal development of Tα1-TP5 fusion peptide.
引文
[1]Goldstein G,Scheid MP,Boyse EA,et al.A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin[J].Science,1979,204:1309-1310.
[2]王玲,魏浩,韦萍,等.固相合成胸腺五肽的研究进展[J].化工进展,2003,2:153-156.
[3]Audhya T,Heavner GA,Kroon DJ,et al.Cooperativity of thymopoietin 32-36the active site and thymopoitin 38-45 in receptor binding[J].Regul Pept,1984,9:155-164.
[4]Gonser S,Crompton NE,Weber PJ,et al.TP5 triggers signal transduction involving mitogen activated protein kinases in monocytes[J].J Rcecpt Signal Transduction Res,1999,19:155-166.
[5]Aiuti F,Businco L,Fiorilli M,et al.Therapy with thymopoietin penta-peptide TP-5 in 26 patients with primary immunodeficiencies[J].Birth Defects Orig Artic Ser,1983,19:267-272.
[6]Takagi S,Minakuchi J,Okawa H,et al.Phenotypical and fnctional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency[J].J Clin Immunol,1989,9:39-47.
[7]Cascinelli N,Belli F,Mascheroni L,et al.Evalution of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients[J].Melanoma Res,1998,8:83-89.
[8]Clemente C,Belli F,Mascheroni L,et al.Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients[J].Melanoma Res,1996,6:63-69.
[9]Sundal E.Thymopentin in cancer[J].Curr Ther Res,1992,51:906-924.
[10]Trinci M,Belli G,Santarelli M,et al.Evalution of the treatment with thymopentin associated with radiotherapy in head and neck tumors[J].Clin Ter, 1995,146:457-467.
[11]Markewitz A,Faist E,Lang S,et al.Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation[J].J Thorac,1993,105:15-24.
[12]Braga M,Costantini E,Di Francesco A,et al.Impact of thymopentin on the incidence and severity of postoperative infection:a randomized controlled trial[J].Br J Surg,1994,81:205-208.
[13]Botusturi M,Panzarasa R,Agostara B,et al.Effects of the immunomodulation in antineoplastic radiation therapy.A Controlled multicenter clinical study[J].Radiol Med,1993,86:327-335.
[14]Stiller MJ,Shupack JL,Kermy C,et al.A doule-blind,placebo-controlled clinical-trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic-dermatitis[J].J Am Acad Dermatol,1994,30(4):597-602..
[15]Hsieh KH,Shalo MF,Liao TN.Thymopentin treatment in severe atopic dermatitis-clinical and immunological evaluations[J].Arch Dis Child,1992,67:1095-1102.
[16]Afeltra A,Galeazzi M,Basso P,et al.Immune imbalance in the synovial fluid of rheumatoid arthritis patients:effects of intra-articular injection of thymopentin[J].J Biol Regul Homeost Agents,1991,5(2):71-75.
[17]Veys EM,Hermanns P,Goldstein G,et al.Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis.Influence of immunomodulating agents[J].Int J Immunopharmacol,1981,3(3):313-319.
[18]Nicoletti F,Zaccone P,Magro G,et al.The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse[J].Scand J Immunol,1994,40(5):549-556.
[19]吴德政,刘琴棣.胸腺五肽在肿瘤化疗中的免疫调节作用[J].中国新药杂志,1999,8(5):321-323.
[20]刘俊达,刘宏伟.合成胸腺五肽在抗衰老中的免疫刺激作用[J].中华老年医学杂志,1993,12(5):269-271.
[21]刘俊达,李昌龙.人工合成胸腺五肽的免疫增强作用[J].中国药学杂志,1992,27(2):82-84.
[22]王勤,杨金波.胸腺生成素Ⅱ活性片断TP-5增强免疫功能的剂量效应[J].兰州大学学报:自然科学版,1992,28(3):128-132.
[23]杨平平.胸腺五肽的免疫学活性及其应用[J].国外医学:药学分册,1989,16(1):19-21.
[24]Heizmann J,Langguth P,Biber A,et al.Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes[J].Peptides,1996,17(7):1083-1089.
[25]Guerin S,Mad B,Femandez E,et al.CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation[J].FASEB J,1997,11(12):1003-1011.
[26]Audhya T,Goldstein G..Comparative efficacy of various routes of administration of thymopentin(TP-5) with consideration of degradative mechanisms[J].Int J Pept Protein Res,1983,22(2):187-193.
[27]郑和昕,吴天凤,江缨,等.胸腺五肽对免疫功能低下的2型糖尿病患者的疗效观察[J].浙江临床医学,2003,5(4):256-257.
[28]Chen C,Li M,Yang H,et al.Roles of Thymosins in cancers and other organ systems[J].World J Surg,2005,29(3):264-270.
[29]Sarandeses CS,Covelo G,Diaz-Jullien C,et al.Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase[J].J Biol Chem,2003,278(15):13286-13293.
[30]宫照龙。胸腺素α1基因的克隆、表达及其对淋巴细胞增值的影响[D].合肥:安徽医科大学,2004.
[31]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide Tα1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19(10):1731-1738.
[32]Romani L,Bistoni F,Gaziano R,et al.Tα1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J].Blood,2004,103(11):4232-4239.
[33]Naz RK,Kaplan P,Badamchian M,et al.Effects of synthetic Tα1 and its analogs on fertilizability of human sperm:search for a biologically active,stable epitope[J].Arch Androl,1995,5(1):63-69.
[34]Spangelo BL,Pompilius M,Farrimond DD,et al.Presence of a peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells[J].Int Immunopharm,2005,5(7-8):1317-1329.
[35]周克夫,赵卿,章军,等.免疫组化方法研究胸腺素α1在小鼠肉瘤S180细胞中的表达[J].厦门大学学报:自然科学版,2005,44(6):741-744.
[36]关有彦,周伟炜.胸腺素在肿瘤研究方面的新进展[J].国外医学:生理、病理科学与临床分册,2001,21(3):209-211.
[37]Moody T W,Leyton J,Farah Z,et al.Thymosinα1 is chemopreventive for lung adenoma formation in A/J mice[J].Cancer Letters,2000(155):121-127.
[38]刘扬东,时德.胸腺素α1在肿瘤治疗中的应用进展[J].中国肿瘤生物治疗杂志,2001,8(2):148-149.
[39]Shrivastava P,Singh SM,Singh N.Antitumor activation of peritoneal macrophages by Tα-1[J].Cancer Invest,2005,23(4):316-322.
[40]卢年芳,黄爱龙,郑瑞强,等.融合蛋白胸腺素α1-干扰素α抗乙型肝炎病毒活性的实验研究[J].中华肝脏病杂志,2005,13(4):252-254.
[41]You J,Zhuang L,Cheng HY,et al.A randomized,controlled,clinical study of Tα-1 versus interferon-α in[corrected]patients with chronic hepatitis B lacking HBeAg in China[J].J Chin Med Assoc,2005,68(2):65-72.
[42]Billich A.Tαl.Sci Clone Pharmaceuticals[J].Curr Opin Investig Drugs,2002,3(5):698-707.
[43]Baumann CA,Badamchian M,Goldstein AL.Tα1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways[J].Mech Ageing Dev,1997,94(1-3):85-101.
[44]Roy R,Singh S M,Shanker A,et al.Mechanism of thymocyte apoptosis induced by serum of tumor-beating host:the molecular events involved and their inhibition by Tα-1[J].Int J Immunopharmacol,2000,22(4):309-321.
[45]Zhang P,Chan J,Dragoi AM,et al.Activation of IKK by Tα1 requires the TRAF6 signalling pathway[J].EMBO Rep,2005,6(6):531-537.
[46]Chadwick D,Pido-Lopez J,Pires A,et al.A pilot study of the safety and efficacy of Tα1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy[J].Clin Exp Immunol,2003,34(3):477-481.
[47]Zhou TY,Zhao LS,Chen M,et al.Immune response enhanced by genes encoding IFN-α 8 and Tα1 co-inoculated with HBV DNA vaccine[J].Zhonghua Gan Zang Bing Za Zhi,2005,13(7):497-500.
[48]Andreone P,Cursaro C,Gramenzi A,et al.In vitro effect of Tα1 and interferon-αon Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C[J].J Viral Hepat,2001,8(3):194-201.
[49]Gokkusu C,Ademoglu E,Oz H,et al.Effects of thymosin alpha-1 on erythrocyte lipid levels and erythrocyte membrane(Na(+)-K+)-ATPase activity in experimental hypercholesterolemia[J].Jpn J Med Sci Biol,1997,50(2):45-53.
[50]Armutcu F,Coskun O,Gurel A,et al.Tα1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats[J].Clin Biochem,2005,38(6):540-547.
[51]Komarcevic A.The modern approach to wound treatment[J].Med Pregl,2000,53(7-8):363-368.
[52]Paul S,Sodhi A.Modulatory role of Tα-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice[J].Immunol Lett,2002,82(3):171-182.
[53]嵇扬.胸腺肽对小鼠腹腔巨噬细胞释放一氧化氮的影响[J].中国生化药物杂志,2001,22(2):74-75.
[54]Sandrine G,Berbard M,Nathalie B,et al.CD10(Endopeptidase 24.11) Is a Thymic Peptide-Degrading Enzyme Possibly Involved in the Regulation of Thymocyte Functions[J].Cell Immunol,1997,175(1):85-91.
[55]朱立平.蛋白质糖基化与B细胞免疫[J].上海免疫学杂志,2001,21(4):193-194.
[56]Roscic M,Horvat S.Transformations of bioactive peptides in the presence of sugars-characterization and stability studies of the adducts generated via the Maillard reaction[J].Bioorg Med Chem,2006,14(14):4933-4943.
[57]Pan CQ,Buxton JM,Yung SL,et al.Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist[J].J Biol Chem,2006,281(18):12506-12515.
[58]Goodson RT,Katre NV.Site-directed PEGylaton of recombinant interleukin-2 at its glycosylation site[J].Biotechnology,1990,8:343-346.
[59]于爱平,蒋中华,钟根深,等.聚乙二醇修饰水蛭素的分离纯化与活性分析[J].药物生物技术,2004,11(5):302-305.
[60]Ligeti M,Bosze S,Csampai A,et al.Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue[J].J Pept Sci,2006,12(7):481-490.
[61]Kocabiyik S,Ozdemir I.Purification and characterization of an intracellular chymotrypsin-like serine protease from Thermoplasma volcanium[J].Biosci Biotechnol Biochem,2006,70(1):126-134.
[62]Chen Y,Vasil AI,Rehaume L,et al.Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides[J].Chem Biol Drug Des,2006,67(2):162-173.
[63]Boeglin D,Xiang Z,Sorenson NB,et al.Aza-scanning of the potent melanocortin receptor agonist Ac-His-d-Phe-Arg-Trp-NH[J].Chem Biol Drug Des,2006,67(4):275-283.
[64]D'Ursi AM,Giannecchini S,Esposito C,et al.Development of antiviral fusion inhibitors:short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus[J].Chembiochem,2006,7(5):774-779.
[65]Zheng J,Ma B,Tsai CJ,et al.Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35[J].Biophys J,2006,91(3):824-833.
[66]Pless J.The history of somatostatin analogs[J].J Endocrinol Invest,2005,28(11Supp1):1-4.
[67]O'Fagain C.Enzyme stabilization:recent experimental progress[J].Enzyme Microb Technol,2003,33(2):137-149.
[68]Osborn BL,Olsen HS,Nardelli B,et al.Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys[J].J Pharmacol Exp Ther,2002,303(2):540-548
[69]唱韶红,巩新,杨志愉,等.人血清白蛋白和人干扰素α-2b的融合蛋白在毕赤酵母中的表达[J].生物工程学报,2006,22(2):173-179.
[70]Yeh P,Landais D,Lemaitre M,et al.Design of yeast- secreted albumin derivatives for human therapy:biological and antiviral properties of a serum albumin-CD4 genetic conjugate[J].Proc Natl Acad Sci USA,1992,89(5):1904-1908.
[71]Ferre R,Badosa E,Feliu L,et al.Inhibition of plant-pathogenic bacteria by short synthetic cecropin a-melittin hybrid peptides[J].Appl Environ Microbiol,2006,72(5):3302-3308.
[72]Anishetty S,Anishetty R,Pennathur G.Understanding mutations and protein stability through tripeptides[J].FEBS Lett,2006,580(8):2071-2080.
[73]Bogdanowich-Knipp SJ,Jois SDS,Siahaan TJ.The effect of conformation on the stability of RGD peptides[J].J Pept Res,1999,53:523-529
[74]Soan C,William SC,Daniel M,et al.Pierschbacher design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha.IIb.beta.3 antagonists[J].J Med Chem,1994,37(1):1-8.
[75]Mamadou AS,Annie M,Frederic L,et al.Synthesis of RGD amphiphilic cyclic peptide as fibrinogen or fibronectin antagonist[J].Lett Pept Sci,1997,4:455-461.
[76]Siemion IZ,Gawlowska M,Krajewski K,et al.Analogs of RGDVY and GRGD peptides inhibit Mycobacterium kansasii phagocytosis[J].Peptides,2003,24(8):1109-1115.
[77]Gilon C,Halle D,Chorev M,et al.Backbone cyclization:A new method for conferring conformatal constraint on peptides[J].Biopolymers,1991,31:745-750.
[78]Bourne G,Goldling SW,Mcgeary RP,et al.The development and application of a novel safety catch Linker for BOC-based assembly of libraries of cyclic peptides[J].J Org Chem,2001,66:7706-7713.
[79]黄小毅,王涛,夏传琴,等.新型含二硫键的环肽的合成[J].有机化学,2004,24(12):1629-1632.
[80]Ranganathan D,Haridas V,Karle IL.Cystinophanes,a novel family of aromatic-bridged cystine cyclic peptides:synthesis,crystal structure,molecular recognition,and conformational studies[J].J Am Chem Soc,1998,120(12):2695-2702.
[81]Shreder K,Zhang L,Dang T,et al.Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue(MABE):A new route to cyclic peptides and peptidomimetics[J].J Med Chem,1998,41(14):2631-2635.
[82]韩前伟,朱晓晴,胡旭波,等.二茂铁类环肽的合成与分子识别研究[J].高等化学学报,2002,23(11):2076-2079.
[83]Jensen KJ,Alsina J,Songster MF,et al.Backbone amide linker(BAL) strategy for solid-phase synthesis of C-terminal-modified and cyclic peptides[J].J Am Chem Soc,1998,120(22):5441-5452.
[84]Ignacy ZS,MonikaG,Krzysztof K,et al.Analogs of RGDVY and GRGD peptides inhibit Mycobacterium Kansasii phagocytosis[J].Peptides,2003,24:1109-1115.
[85]Berezowska I,Chung NN,Lemieux C,et al.Cyclic dermorphin tetrapeptide analogues obtained via ring-closing metathesis[J].Acta Biochim Pol,2006,53(1):73-76.
[86]Natarajan T,Ikramul H,Rana TM.Design,synthesis,and 3 biological activity of a cyclic peptide:an inhibitor of HIV-1 TAR interactions in human cells[J].Bioorg Med Chem Lett,2000,10:971-974.
[87]杨献光,齐志广,赵宝存,等.碱裂解法提取质粒DNA的研究[J].生物技术通报,2003,6:23-24.
[88]卢圣栋.现代分子生物学实验技术[M].第一版.北京:高等教育出版社,1993:113-114.
[89]剧海,梁东春,郭刚,等.用于PCR实验的毕赤酵母基因组DNA制备方法的比较[J].天津医药,2003,32(5):270-272.
[90]O'Fagain C.Enzyme stabilization:recent experimental progress.Enzyme Microb[J].Technol,2003,33:137-149.
[91]Zheng J,Ma B,Tsai CJ,et al.Structural Stability and Dynamics of an Amyloid-forming Peptide GNNQQNY from the Yeast Prion Sup-35[J].Biophys J,2006,91:824-833.
[92]林陈水,黎小军,王平,等.人胸腺素α1基因工程菌的构建与表达[J].浙江工业大学学报,2005,33(3):306-309.
[93]宫照龙,徐义辉,展瑞,等.胸腺素α1串联体的表达、纯化及生物学活性检测[J].中国生物制品学杂志,2005,18(2):111-114.
[94]王景林,侯世勇,康琳.胸腺素α1/干扰素α-2b融合基因表达载体的构建与表达[J].生命科学研究,2004,8(3):242-244.
[95]Weiss HM,Haase W,Michel H,et al.Expression of functional mouse 5 HT5A seroton receptor in the methylotrophic yeast Pichia pastoris.Pharmacological characterization and localization[J].FEBS lett,1995,377:451-456.
[96]Julius D,Brake A,Blair L,et al.Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro-alpha-factor[J].Cell,1984,37(3):1075-1089.
[97]Waterham HR,Digan ME,Koutz PJ,et al.Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter[J].Gene,1997,186(1):37-44.
[98]Cos O,Ramon R,Montesinos JL,et al.Operational strategies,monitoring and control of heterologous protein production in the methylotrophic yeast Pichia pastoris under different promoters:A review[J].Microb Cell Fact,2006,5:17.
[99]张博润,何秀萍,陈玉梅,等.酵母菌载体系统研究进展[J].微生物通报,1998,25(5):42-45.
[100]张素芳,曹瑞兵,瑞兵,等.杂合抗菌肽CecA-mil的改造及在毕赤酵母中的分泌表达[J].微生物学报,2005,45(2):218-222.
[101]李洪钊,李亮助,孙强明,等.巴斯德毕赤酵母表达系统优化策略[J].微生物学报,2003,43(2):288-292.
[102]Sreekrishna K,Brankamp RG,Kropp KE,et al.Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris[J].Gene,1997,190(1):55-62.
[103]Clare J,Scorer C,Buckholz R,et al.Expression of EGF and HIV envelope glycoprotein[J].Methods Mol Biol,1998,103:209-225.
[104]聂东宋,梁宋平,李敏.外源蛋白在巴氏毕赤酵母中高效表达的策略[J].吉首大学学报(自然科学版),2001,22(3):112-116.
[105]华慧,周思翔,王正荣.外源基因在巴斯德毕赤酵母中的表达[J].外国外医学生物医学工程分册,2003,26(3):112-117.
[106]Cereghino GP,Cereghino JL,Ilgen C,et al.Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris[J].Curr Opin Biotechnol,2002,13(4):329-332.
[107]韦宇拓,甘凤琼,苏华波,等.巴斯德毕赤酵母新型分泌表达载体构建[J].广西农业生物科学,2001,22(1):40-44.
[108]Kim M,Elvin C,Brownlee A,et al.High yield expression of recombinant pro-resilin:lactose-induced fermentation in E.coli and facile purification[J]..Protein Expr Purif,2007,52(1):230-236.
[109]林陈水,黎小军,王平,等.人胸腺素α1基因工程菌的构建与表达[J].浙江工业大学学报,2005,33(3):306-309.
[110]宫照龙,徐义辉,展瑞,等.胸腺素α1串联体的表达,纯化及生物学活性检测[J].中国生物制品学杂志,2005,18(2):111-114.
[111]章如安,杨晟,邱荣德,等.巴斯德毕赤酵母表达体系研究进展[J].微生物通报,2000,27(5):371-373.
[112]Li Z,Xiong F,Lin Q,et al.Low-temperature increases the yield of biologically active herring antifreeze protein in Pichia pastoris[J].Protein Expr Purif,2001,21(3):438-45.
[113]www.invitrogen,com.
[114]Whittaker MM,Whittaker JW.Expression of Recombinant Galactose Oxidase by Pichia pastoris[J].Protein Expr Purif,2000,20:105-111.
[115]Clare JJ,Rayment FB,Ballantine SP,et al.High-level expression of tatanus multiple tandem integrations of the gene[J].Bio Technology,1991,9:455-460.
[116]Fairlie WD,Zhang H,Brown PK,et al.Expression of a TGF-beta superfamily protein,macrophage inhibitory cytokines-1,in the yeast Pichia pastoris[J].Gene,2000,254(1-2):67-76.
[117]Murphy KPJr,Gagne P,Pazmany C,et al.Expression of human interleukin-17in Pichia pastoris:purification and characterization[J].Protein Expr Purif,1998,12(2):208-214.
[118]Clare JJ,Romanos MA,Rayment FB,et al.Production of mouse epidermal growth factor in yeast:high-level secretion using Pichia pastoris strains[J].Gene,1991,105(2):205-212.
[119]Sreekrishna K,Nelles L,Potenz R,et al.High-level expression,purification,and characterization of recombinant human tumor necrosis factor synthesized in the methylotrophic yeast pichia pastoris[J].Bio chemistry,1989,28(9):4117-4125.
[120]Thielens NM,Enrie K,Lacroix M,et al.The N-terminal CUB-epidermal growth factor module pair of human complement protease C1r binds Ca~2+ with high affinity and mediates Ca~(2+)-dependent interaction with C1s[J].J Biol Chem,1999,274(14):9149-9159.
[121]Th(o|¨)mmes J,Halfar M,Gieren H,et al.Human chymotrypsinogen B production from Pichia pastoris by integrated development of fermentation and downstream processing.Part 2.Protein recovery[J].Biotechnol Prog,2001,17(3):503-512.
[122]http://faculty.kgi.edu/cregg/Pichia2004.htm.
[123]陆健.蛋白质纯化技术及应用[M].北京:化学工业出版社,2005:56.
[124]沈星灿,梁宏,何锡文,等.圆二色谱分析蛋白质构象方法及研究进展[J].分析化学,2004,32(3):388-394.
[125]Johnson WC.Analyzing protein circular dichroism spectra for accurate secondary structures[J].Proteins,1999,35(3):307-312.
[126]Sreerama N,Venyaminov SY,Woody RW.Estimation of protein secondary structure from CD spectra:Inclusion of denatured proteins with native protein in the analysis[J].Anal Biochem,2000,287(2):243-251.
[127]吴瑾光.近代傅里叶变换红外光谱技术及应用(下卷)[M].北京:科学技术文献出版社,1994:192-218.
[128]Byler DM,Susi H.Examination of the secondary structure of proteins by deconvolved FTIR spectra[J].Bioploymers,1986,25(3):469-487.
[129]Byler DM,Bouillette JN,Susi H.Quantitative studies of protein structure by FT-IR spectra deconvolution and curve-fitting[J].Spectroscopy,1986,1(3):29-32.
[130]Pelton,JT,Melean LR,Spectroscopic methods for anaylsis of protein secondary structure[J].Anal Biochem,2000,277:167-176.
[131]Kaiden K,Matsui T,Tanaka S.A study of the amide Ⅲ by FTIR spectrometry of the secondary structure of albumin,myoglobin and γ-globulin[J].Appl Spectrosc,I987,41(2):180-184.
[132]谢孟峡,刘嫒.红外光谱酰胺Ⅲ带用于蛋白质二级结构的测定研究[J].高等学校化学学报,2003,24(2):226-231.
[133]卞为东,孙素琴,黄岳顺,等.FTIR光谱法研究天花粉蛋白的热去折叠过程[J].光谱学与光谱分析,2000,24(4):471-473.
[134]林克椿.医学生物物理学[M].北京:北京大学医学出版社,1999.
[135]汪猷,金善炜.天花粉蛋白(第二版)[M].北京:科学出版社,2000,40-60.
[136]杨频,高飞.生物无机化学原理[M].北京:科学出版社,2002,430-353.
[137]蔡国友,侯玉霞.应用圆二色光谱研究交变应力对烟草细胞膜蛋白结构的影响[J].光子学报,2000,29(4):289-292.
[138]程源,苏静.影响多肽与花粉钙调素亲和性的因素一多肽的圆二色性及核磁共振研究[J].高等学校化学学报,2001,22(5):785-787.
[139]Susi H,Byler DM.Resolution-enhanced Fourier transformation infrared spectroscopy of enzymes[J].Methods Enzymol,1986,130:290-311.
[140]秦身钧,王建滨,姚宏伟,等.计算机辅助解析FTIR定量研究蛋白质构象的用进展[J].河北师范大学学报(自然科学版),2006,30(3):331-335
[141]Bandekar J.Amide modes and protein conformation[J].Biochim Biophys Acta. 1992,1120(2):123-143.
[142]Tuthill CW,Rudolph A,Li Y,et al.Quantitative analysis of thymosin α1 in human serum by LC-MS/MS[J].AAPS Pharm Sci Tech,2000,1:E11
[143]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19:1731-1738.
[144]孙会仙,张淑珍,谢剑炜.蛋白多肽类药物的药代动力学分析方法的研究进展[J].国外医学(药学分册),2006,33(1):63-66.
[145]Gallwitz B,Ropeter T,Morys-Wortmann C,et al.GLP-1-analogues resistant to degradation by dipeptidyl-peptidase Ⅳ in vitro[J].Regul Pept,2000,29,86(1-3):103-111.
[146]Wen JY,Ledger R,McLeod B J,et al.Enzymatic degradation of luteinizing hormone releasing hormone(LHRH) by mucosal homogenates from the intestine of the common brushtail possum(Trichosurus vulpecula)[J].Life Sci,2002,71(25):3019-3030.
[147]Besser D,Muller B,Kleinwachter P,et al.Synthesis and characterization of octapeptide somatostatin analogues with backbone cyclization[J].J Prakt Chem,2000,342(6):537-545.
[148]Amoscato AA,Balasubramaniam A,Alexander JW,et al.Degradation of thymopentin by human lymphocytes:evidence for aminopeptidase activity[J].Biochim Biophys Acta,1988,955:164-174.
[149]Sisto A,Mariotti S,Groggia A,et al.Biologically active retro-inverso analogs of thymopentin[J].Pept Chem Struct Biol Proc Am Pept Symp,1989,11:772-773.
[150]尹雅姝,陈大为,乔明曦,等.RP-HPLC法测定胸腺五肽溶液的稳定性[J].沈阳药科大学学报,2007,24(2):89-93.
[151]刘璐,宋月英,张庆云,等.HPLC法测定胸腺五肽的含量[J].中国药房,2007,18(28):2210-2211.
[152]Kraemer W J,Noble B,Culver B,et al.Changes in plasma proenkephalin peptide F and catecholamine levels during graded exercise in men[J].Proc Natl Acad Sci USA,1985,82(18):6349-6351.
[153]DeGraw JI,Almquist RG,Hiebert CK,et al.Stabilized analogs of thymopentin,1.4,5-ketomethylene pseudopeptides[J].J Med Chem,1997,40:2386-2397.
[154]唐仕炜,袁晓佳,张志荣,等.胸腺五肽三甲基壳聚糖口服纳米粒的研究[J].四川大学学报(医学版),2007,38(5):885-888
[155]Chi Q,Xie X,Zhang J,et al.Synthesis,characterization and biological activities of thymopentin ethyl ester[J].Pharmazie,2008,63(11):784-787.
[156]焦玉焕,孙考祥,慕宏杰,等.胸腺五肽缓释多囊脂质体的制备及大鼠药物代谢动力学的初步研究[J].药学学报,2008,43(7):756-760
[157]Pignatello R,Pecora TM.Conjugmion of thymopentin(TP5)with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity[J].Pharmazie,2007,62(9):663-667.
[158]朱颐申,姚忠,邱芊,等.胸腺五肽肽库制备及其免疫活性分析[J].中国生化药物杂志,2005,26(5):257-260.
[159]DeGraw JI,Almquist RG,Hiebert CK,et al.Stabilized analogs of thymopentin.2.1,2- and 3,4-ketomethylene pseudopeptides[J].J Med Chem,1997,40:2398-2406.
[160]Smith RL,Dousman L,Waud WR,et al.Stabilized analogs of thymopentin.3.valuation of ketomethylene pseudopeptides for antiarthfitic properties[J].J Med Chem,1997,40:2407-2411.
[161]Sharma P,Anuradha,Rohatgi A,et al.Stimulation of nonspecific resistance by thymopentin and its analogs against leishmania donovani infection in hamsters[J].Peptides,1999,20:1381-1383.
[162]余榕捷,高媛,林剑,等.重组环状胸腺五肽结构类似物Cyclo-(Cys-Arg-Lys -Asp-Val-Tyr-)的制备,鉴定和活性检测[J].中国生物化学与分子生物学报,22(8):652-658.
[163]Wieczorek Z,Zimecki M,Trojnar J,et al.Immunomodulatory activity of a potent thymopentin analog:disulphide bridged beta-mercaptopropionyl-arginyl -lysyl-aspartyl-valyl-tyrosyl-cysteine amide[J].Pol J Pharmacol,1996, 48(1):31-38.
[164]Heavner GA,Audhya T,Doyle D,et al.Biologically active conformations of thymopentin.Studies with conformationally restricted analogs[J].Int J Pept Protein Res,1991,37(3):198-209.
[165]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19:1731-1738.
[166]成静,祝寿芬.三氧化二砷对小鼠免疫系统的影响[J].中国地方病学杂志,2000,1(1):41-43.
[167]曹志然,周文英,陈淑兰,等.十全大补汤对小鼠免疫功能影响的实验研究[J].中国中医基础医学杂志,2000,10(6):34-35.
[168]林学颜,张玲.现代细胞与分子免疫学(第二版)[M].科学出版社,北京:2000.
[169]Denes L,Szende B,Ember J,et al.Immunoregulating peptides Ⅱ.In vitro effects of TP5 analogs on E-rosette formation and cell division[J].Immunopharmaeol Immunotoxicol,1987,9(1):1-18.
[170]John WH.Aspects of the immunopharmacology of thymosin α1[J].Clin Appl Rev,2001,1(3):187-191.
[171]石继红,张英起,赵永同,等.胸腺素α1基因的克隆表达及其生物活性[J].中国生物化学与分子生物学报,2001,17(3):344-349.
[172]Tischio TP,Patrick JE,Weintraub HS,et al.Short in vitro half-life of thymopoietin pentapeptide in human plasma[J],Int J Pept Protein Res,1983,14:479-484.
[173]Kwon KH,Kim KI,Jun WJ,et al.In vitro and in vivo effects of macrophage-stimulatory polysaccharide from leaves of Perilla frutescens var.crispa[J].Biol pharm Bull,2002,25:367-371.
[174]王红梅,马玲,姚小曼.小鼠廓清实验方法比较[J].中国食品卫生杂志,2000,12(3):3-5.
[175]李小定,吴谋成,曾晓波,等.灰树花多糖粗品与纯品的抗肿瘤作用及对免疫功能的影响[J].营养学报,2003,25(1):7-9.
[176]孙翠慈,王安利,王素芬,等.活性多糖对水产动物免疫功能的调节[J].海洋通报,2003,22(3):81-89.
[2]王玲,魏浩,韦萍,等.固相合成胸腺五肽的研究进展[J].化工进展,2003,2:153-156.
[3]Audhya T,Heavner GA,Kroon DJ,et al.Cooperativity of thymopoietin 32-36the active site and thymopoitin 38-45 in receptor binding[J].Regul Pept,1984,9:155-164.
[4]Gonser S,Crompton NE,Weber PJ,et al.TP5 triggers signal transduction involving mitogen activated protein kinases in monocytes[J].J Rcecpt Signal Transduction Res,1999,19:155-166.
[5]Aiuti F,Businco L,Fiorilli M,et al.Therapy with thymopoietin penta-peptide TP-5 in 26 patients with primary immunodeficiencies[J].Birth Defects Orig Artic Ser,1983,19:267-272.
[6]Takagi S,Minakuchi J,Okawa H,et al.Phenotypical and fnctional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency[J].J Clin Immunol,1989,9:39-47.
[7]Cascinelli N,Belli F,Mascheroni L,et al.Evalution of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients[J].Melanoma Res,1998,8:83-89.
[8]Clemente C,Belli F,Mascheroni L,et al.Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients[J].Melanoma Res,1996,6:63-69.
[9]Sundal E.Thymopentin in cancer[J].Curr Ther Res,1992,51:906-924.
[10]Trinci M,Belli G,Santarelli M,et al.Evalution of the treatment with thymopentin associated with radiotherapy in head and neck tumors[J].Clin Ter, 1995,146:457-467.
[11]Markewitz A,Faist E,Lang S,et al.Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation[J].J Thorac,1993,105:15-24.
[12]Braga M,Costantini E,Di Francesco A,et al.Impact of thymopentin on the incidence and severity of postoperative infection:a randomized controlled trial[J].Br J Surg,1994,81:205-208.
[13]Botusturi M,Panzarasa R,Agostara B,et al.Effects of the immunomodulation in antineoplastic radiation therapy.A Controlled multicenter clinical study[J].Radiol Med,1993,86:327-335.
[14]Stiller MJ,Shupack JL,Kermy C,et al.A doule-blind,placebo-controlled clinical-trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic-dermatitis[J].J Am Acad Dermatol,1994,30(4):597-602..
[15]Hsieh KH,Shalo MF,Liao TN.Thymopentin treatment in severe atopic dermatitis-clinical and immunological evaluations[J].Arch Dis Child,1992,67:1095-1102.
[16]Afeltra A,Galeazzi M,Basso P,et al.Immune imbalance in the synovial fluid of rheumatoid arthritis patients:effects of intra-articular injection of thymopentin[J].J Biol Regul Homeost Agents,1991,5(2):71-75.
[17]Veys EM,Hermanns P,Goldstein G,et al.Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis.Influence of immunomodulating agents[J].Int J Immunopharmacol,1981,3(3):313-319.
[18]Nicoletti F,Zaccone P,Magro G,et al.The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse[J].Scand J Immunol,1994,40(5):549-556.
[19]吴德政,刘琴棣.胸腺五肽在肿瘤化疗中的免疫调节作用[J].中国新药杂志,1999,8(5):321-323.
[20]刘俊达,刘宏伟.合成胸腺五肽在抗衰老中的免疫刺激作用[J].中华老年医学杂志,1993,12(5):269-271.
[21]刘俊达,李昌龙.人工合成胸腺五肽的免疫增强作用[J].中国药学杂志,1992,27(2):82-84.
[22]王勤,杨金波.胸腺生成素Ⅱ活性片断TP-5增强免疫功能的剂量效应[J].兰州大学学报:自然科学版,1992,28(3):128-132.
[23]杨平平.胸腺五肽的免疫学活性及其应用[J].国外医学:药学分册,1989,16(1):19-21.
[24]Heizmann J,Langguth P,Biber A,et al.Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes[J].Peptides,1996,17(7):1083-1089.
[25]Guerin S,Mad B,Femandez E,et al.CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation[J].FASEB J,1997,11(12):1003-1011.
[26]Audhya T,Goldstein G..Comparative efficacy of various routes of administration of thymopentin(TP-5) with consideration of degradative mechanisms[J].Int J Pept Protein Res,1983,22(2):187-193.
[27]郑和昕,吴天凤,江缨,等.胸腺五肽对免疫功能低下的2型糖尿病患者的疗效观察[J].浙江临床医学,2003,5(4):256-257.
[28]Chen C,Li M,Yang H,et al.Roles of Thymosins in cancers and other organ systems[J].World J Surg,2005,29(3):264-270.
[29]Sarandeses CS,Covelo G,Diaz-Jullien C,et al.Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase[J].J Biol Chem,2003,278(15):13286-13293.
[30]宫照龙。胸腺素α1基因的克隆、表达及其对淋巴细胞增值的影响[D].合肥:安徽医科大学,2004.
[31]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide Tα1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19(10):1731-1738.
[32]Romani L,Bistoni F,Gaziano R,et al.Tα1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J].Blood,2004,103(11):4232-4239.
[33]Naz RK,Kaplan P,Badamchian M,et al.Effects of synthetic Tα1 and its analogs on fertilizability of human sperm:search for a biologically active,stable epitope[J].Arch Androl,1995,5(1):63-69.
[34]Spangelo BL,Pompilius M,Farrimond DD,et al.Presence of a peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells[J].Int Immunopharm,2005,5(7-8):1317-1329.
[35]周克夫,赵卿,章军,等.免疫组化方法研究胸腺素α1在小鼠肉瘤S180细胞中的表达[J].厦门大学学报:自然科学版,2005,44(6):741-744.
[36]关有彦,周伟炜.胸腺素在肿瘤研究方面的新进展[J].国外医学:生理、病理科学与临床分册,2001,21(3):209-211.
[37]Moody T W,Leyton J,Farah Z,et al.Thymosinα1 is chemopreventive for lung adenoma formation in A/J mice[J].Cancer Letters,2000(155):121-127.
[38]刘扬东,时德.胸腺素α1在肿瘤治疗中的应用进展[J].中国肿瘤生物治疗杂志,2001,8(2):148-149.
[39]Shrivastava P,Singh SM,Singh N.Antitumor activation of peritoneal macrophages by Tα-1[J].Cancer Invest,2005,23(4):316-322.
[40]卢年芳,黄爱龙,郑瑞强,等.融合蛋白胸腺素α1-干扰素α抗乙型肝炎病毒活性的实验研究[J].中华肝脏病杂志,2005,13(4):252-254.
[41]You J,Zhuang L,Cheng HY,et al.A randomized,controlled,clinical study of Tα-1 versus interferon-α in[corrected]patients with chronic hepatitis B lacking HBeAg in China[J].J Chin Med Assoc,2005,68(2):65-72.
[42]Billich A.Tαl.Sci Clone Pharmaceuticals[J].Curr Opin Investig Drugs,2002,3(5):698-707.
[43]Baumann CA,Badamchian M,Goldstein AL.Tα1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways[J].Mech Ageing Dev,1997,94(1-3):85-101.
[44]Roy R,Singh S M,Shanker A,et al.Mechanism of thymocyte apoptosis induced by serum of tumor-beating host:the molecular events involved and their inhibition by Tα-1[J].Int J Immunopharmacol,2000,22(4):309-321.
[45]Zhang P,Chan J,Dragoi AM,et al.Activation of IKK by Tα1 requires the TRAF6 signalling pathway[J].EMBO Rep,2005,6(6):531-537.
[46]Chadwick D,Pido-Lopez J,Pires A,et al.A pilot study of the safety and efficacy of Tα1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy[J].Clin Exp Immunol,2003,34(3):477-481.
[47]Zhou TY,Zhao LS,Chen M,et al.Immune response enhanced by genes encoding IFN-α 8 and Tα1 co-inoculated with HBV DNA vaccine[J].Zhonghua Gan Zang Bing Za Zhi,2005,13(7):497-500.
[48]Andreone P,Cursaro C,Gramenzi A,et al.In vitro effect of Tα1 and interferon-αon Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C[J].J Viral Hepat,2001,8(3):194-201.
[49]Gokkusu C,Ademoglu E,Oz H,et al.Effects of thymosin alpha-1 on erythrocyte lipid levels and erythrocyte membrane(Na(+)-K+)-ATPase activity in experimental hypercholesterolemia[J].Jpn J Med Sci Biol,1997,50(2):45-53.
[50]Armutcu F,Coskun O,Gurel A,et al.Tα1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats[J].Clin Biochem,2005,38(6):540-547.
[51]Komarcevic A.The modern approach to wound treatment[J].Med Pregl,2000,53(7-8):363-368.
[52]Paul S,Sodhi A.Modulatory role of Tα-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice[J].Immunol Lett,2002,82(3):171-182.
[53]嵇扬.胸腺肽对小鼠腹腔巨噬细胞释放一氧化氮的影响[J].中国生化药物杂志,2001,22(2):74-75.
[54]Sandrine G,Berbard M,Nathalie B,et al.CD10(Endopeptidase 24.11) Is a Thymic Peptide-Degrading Enzyme Possibly Involved in the Regulation of Thymocyte Functions[J].Cell Immunol,1997,175(1):85-91.
[55]朱立平.蛋白质糖基化与B细胞免疫[J].上海免疫学杂志,2001,21(4):193-194.
[56]Roscic M,Horvat S.Transformations of bioactive peptides in the presence of sugars-characterization and stability studies of the adducts generated via the Maillard reaction[J].Bioorg Med Chem,2006,14(14):4933-4943.
[57]Pan CQ,Buxton JM,Yung SL,et al.Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist[J].J Biol Chem,2006,281(18):12506-12515.
[58]Goodson RT,Katre NV.Site-directed PEGylaton of recombinant interleukin-2 at its glycosylation site[J].Biotechnology,1990,8:343-346.
[59]于爱平,蒋中华,钟根深,等.聚乙二醇修饰水蛭素的分离纯化与活性分析[J].药物生物技术,2004,11(5):302-305.
[60]Ligeti M,Bosze S,Csampai A,et al.Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue[J].J Pept Sci,2006,12(7):481-490.
[61]Kocabiyik S,Ozdemir I.Purification and characterization of an intracellular chymotrypsin-like serine protease from Thermoplasma volcanium[J].Biosci Biotechnol Biochem,2006,70(1):126-134.
[62]Chen Y,Vasil AI,Rehaume L,et al.Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides[J].Chem Biol Drug Des,2006,67(2):162-173.
[63]Boeglin D,Xiang Z,Sorenson NB,et al.Aza-scanning of the potent melanocortin receptor agonist Ac-His-d-Phe-Arg-Trp-NH[J].Chem Biol Drug Des,2006,67(4):275-283.
[64]D'Ursi AM,Giannecchini S,Esposito C,et al.Development of antiviral fusion inhibitors:short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus[J].Chembiochem,2006,7(5):774-779.
[65]Zheng J,Ma B,Tsai CJ,et al.Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35[J].Biophys J,2006,91(3):824-833.
[66]Pless J.The history of somatostatin analogs[J].J Endocrinol Invest,2005,28(11Supp1):1-4.
[67]O'Fagain C.Enzyme stabilization:recent experimental progress[J].Enzyme Microb Technol,2003,33(2):137-149.
[68]Osborn BL,Olsen HS,Nardelli B,et al.Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys[J].J Pharmacol Exp Ther,2002,303(2):540-548
[69]唱韶红,巩新,杨志愉,等.人血清白蛋白和人干扰素α-2b的融合蛋白在毕赤酵母中的表达[J].生物工程学报,2006,22(2):173-179.
[70]Yeh P,Landais D,Lemaitre M,et al.Design of yeast- secreted albumin derivatives for human therapy:biological and antiviral properties of a serum albumin-CD4 genetic conjugate[J].Proc Natl Acad Sci USA,1992,89(5):1904-1908.
[71]Ferre R,Badosa E,Feliu L,et al.Inhibition of plant-pathogenic bacteria by short synthetic cecropin a-melittin hybrid peptides[J].Appl Environ Microbiol,2006,72(5):3302-3308.
[72]Anishetty S,Anishetty R,Pennathur G.Understanding mutations and protein stability through tripeptides[J].FEBS Lett,2006,580(8):2071-2080.
[73]Bogdanowich-Knipp SJ,Jois SDS,Siahaan TJ.The effect of conformation on the stability of RGD peptides[J].J Pept Res,1999,53:523-529
[74]Soan C,William SC,Daniel M,et al.Pierschbacher design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha.IIb.beta.3 antagonists[J].J Med Chem,1994,37(1):1-8.
[75]Mamadou AS,Annie M,Frederic L,et al.Synthesis of RGD amphiphilic cyclic peptide as fibrinogen or fibronectin antagonist[J].Lett Pept Sci,1997,4:455-461.
[76]Siemion IZ,Gawlowska M,Krajewski K,et al.Analogs of RGDVY and GRGD peptides inhibit Mycobacterium kansasii phagocytosis[J].Peptides,2003,24(8):1109-1115.
[77]Gilon C,Halle D,Chorev M,et al.Backbone cyclization:A new method for conferring conformatal constraint on peptides[J].Biopolymers,1991,31:745-750.
[78]Bourne G,Goldling SW,Mcgeary RP,et al.The development and application of a novel safety catch Linker for BOC-based assembly of libraries of cyclic peptides[J].J Org Chem,2001,66:7706-7713.
[79]黄小毅,王涛,夏传琴,等.新型含二硫键的环肽的合成[J].有机化学,2004,24(12):1629-1632.
[80]Ranganathan D,Haridas V,Karle IL.Cystinophanes,a novel family of aromatic-bridged cystine cyclic peptides:synthesis,crystal structure,molecular recognition,and conformational studies[J].J Am Chem Soc,1998,120(12):2695-2702.
[81]Shreder K,Zhang L,Dang T,et al.Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue(MABE):A new route to cyclic peptides and peptidomimetics[J].J Med Chem,1998,41(14):2631-2635.
[82]韩前伟,朱晓晴,胡旭波,等.二茂铁类环肽的合成与分子识别研究[J].高等化学学报,2002,23(11):2076-2079.
[83]Jensen KJ,Alsina J,Songster MF,et al.Backbone amide linker(BAL) strategy for solid-phase synthesis of C-terminal-modified and cyclic peptides[J].J Am Chem Soc,1998,120(22):5441-5452.
[84]Ignacy ZS,MonikaG,Krzysztof K,et al.Analogs of RGDVY and GRGD peptides inhibit Mycobacterium Kansasii phagocytosis[J].Peptides,2003,24:1109-1115.
[85]Berezowska I,Chung NN,Lemieux C,et al.Cyclic dermorphin tetrapeptide analogues obtained via ring-closing metathesis[J].Acta Biochim Pol,2006,53(1):73-76.
[86]Natarajan T,Ikramul H,Rana TM.Design,synthesis,and 3 biological activity of a cyclic peptide:an inhibitor of HIV-1 TAR interactions in human cells[J].Bioorg Med Chem Lett,2000,10:971-974.
[87]杨献光,齐志广,赵宝存,等.碱裂解法提取质粒DNA的研究[J].生物技术通报,2003,6:23-24.
[88]卢圣栋.现代分子生物学实验技术[M].第一版.北京:高等教育出版社,1993:113-114.
[89]剧海,梁东春,郭刚,等.用于PCR实验的毕赤酵母基因组DNA制备方法的比较[J].天津医药,2003,32(5):270-272.
[90]O'Fagain C.Enzyme stabilization:recent experimental progress.Enzyme Microb[J].Technol,2003,33:137-149.
[91]Zheng J,Ma B,Tsai CJ,et al.Structural Stability and Dynamics of an Amyloid-forming Peptide GNNQQNY from the Yeast Prion Sup-35[J].Biophys J,2006,91:824-833.
[92]林陈水,黎小军,王平,等.人胸腺素α1基因工程菌的构建与表达[J].浙江工业大学学报,2005,33(3):306-309.
[93]宫照龙,徐义辉,展瑞,等.胸腺素α1串联体的表达、纯化及生物学活性检测[J].中国生物制品学杂志,2005,18(2):111-114.
[94]王景林,侯世勇,康琳.胸腺素α1/干扰素α-2b融合基因表达载体的构建与表达[J].生命科学研究,2004,8(3):242-244.
[95]Weiss HM,Haase W,Michel H,et al.Expression of functional mouse 5 HT5A seroton receptor in the methylotrophic yeast Pichia pastoris.Pharmacological characterization and localization[J].FEBS lett,1995,377:451-456.
[96]Julius D,Brake A,Blair L,et al.Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro-alpha-factor[J].Cell,1984,37(3):1075-1089.
[97]Waterham HR,Digan ME,Koutz PJ,et al.Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter[J].Gene,1997,186(1):37-44.
[98]Cos O,Ramon R,Montesinos JL,et al.Operational strategies,monitoring and control of heterologous protein production in the methylotrophic yeast Pichia pastoris under different promoters:A review[J].Microb Cell Fact,2006,5:17.
[99]张博润,何秀萍,陈玉梅,等.酵母菌载体系统研究进展[J].微生物通报,1998,25(5):42-45.
[100]张素芳,曹瑞兵,瑞兵,等.杂合抗菌肽CecA-mil的改造及在毕赤酵母中的分泌表达[J].微生物学报,2005,45(2):218-222.
[101]李洪钊,李亮助,孙强明,等.巴斯德毕赤酵母表达系统优化策略[J].微生物学报,2003,43(2):288-292.
[102]Sreekrishna K,Brankamp RG,Kropp KE,et al.Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris[J].Gene,1997,190(1):55-62.
[103]Clare J,Scorer C,Buckholz R,et al.Expression of EGF and HIV envelope glycoprotein[J].Methods Mol Biol,1998,103:209-225.
[104]聂东宋,梁宋平,李敏.外源蛋白在巴氏毕赤酵母中高效表达的策略[J].吉首大学学报(自然科学版),2001,22(3):112-116.
[105]华慧,周思翔,王正荣.外源基因在巴斯德毕赤酵母中的表达[J].外国外医学生物医学工程分册,2003,26(3):112-117.
[106]Cereghino GP,Cereghino JL,Ilgen C,et al.Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris[J].Curr Opin Biotechnol,2002,13(4):329-332.
[107]韦宇拓,甘凤琼,苏华波,等.巴斯德毕赤酵母新型分泌表达载体构建[J].广西农业生物科学,2001,22(1):40-44.
[108]Kim M,Elvin C,Brownlee A,et al.High yield expression of recombinant pro-resilin:lactose-induced fermentation in E.coli and facile purification[J]..Protein Expr Purif,2007,52(1):230-236.
[109]林陈水,黎小军,王平,等.人胸腺素α1基因工程菌的构建与表达[J].浙江工业大学学报,2005,33(3):306-309.
[110]宫照龙,徐义辉,展瑞,等.胸腺素α1串联体的表达,纯化及生物学活性检测[J].中国生物制品学杂志,2005,18(2):111-114.
[111]章如安,杨晟,邱荣德,等.巴斯德毕赤酵母表达体系研究进展[J].微生物通报,2000,27(5):371-373.
[112]Li Z,Xiong F,Lin Q,et al.Low-temperature increases the yield of biologically active herring antifreeze protein in Pichia pastoris[J].Protein Expr Purif,2001,21(3):438-45.
[113]www.invitrogen,com.
[114]Whittaker MM,Whittaker JW.Expression of Recombinant Galactose Oxidase by Pichia pastoris[J].Protein Expr Purif,2000,20:105-111.
[115]Clare JJ,Rayment FB,Ballantine SP,et al.High-level expression of tatanus multiple tandem integrations of the gene[J].Bio Technology,1991,9:455-460.
[116]Fairlie WD,Zhang H,Brown PK,et al.Expression of a TGF-beta superfamily protein,macrophage inhibitory cytokines-1,in the yeast Pichia pastoris[J].Gene,2000,254(1-2):67-76.
[117]Murphy KPJr,Gagne P,Pazmany C,et al.Expression of human interleukin-17in Pichia pastoris:purification and characterization[J].Protein Expr Purif,1998,12(2):208-214.
[118]Clare JJ,Romanos MA,Rayment FB,et al.Production of mouse epidermal growth factor in yeast:high-level secretion using Pichia pastoris strains[J].Gene,1991,105(2):205-212.
[119]Sreekrishna K,Nelles L,Potenz R,et al.High-level expression,purification,and characterization of recombinant human tumor necrosis factor synthesized in the methylotrophic yeast pichia pastoris[J].Bio chemistry,1989,28(9):4117-4125.
[120]Thielens NM,Enrie K,Lacroix M,et al.The N-terminal CUB-epidermal growth factor module pair of human complement protease C1r binds Ca~2+ with high affinity and mediates Ca~(2+)-dependent interaction with C1s[J].J Biol Chem,1999,274(14):9149-9159.
[121]Th(o|¨)mmes J,Halfar M,Gieren H,et al.Human chymotrypsinogen B production from Pichia pastoris by integrated development of fermentation and downstream processing.Part 2.Protein recovery[J].Biotechnol Prog,2001,17(3):503-512.
[122]http://faculty.kgi.edu/cregg/Pichia2004.htm.
[123]陆健.蛋白质纯化技术及应用[M].北京:化学工业出版社,2005:56.
[124]沈星灿,梁宏,何锡文,等.圆二色谱分析蛋白质构象方法及研究进展[J].分析化学,2004,32(3):388-394.
[125]Johnson WC.Analyzing protein circular dichroism spectra for accurate secondary structures[J].Proteins,1999,35(3):307-312.
[126]Sreerama N,Venyaminov SY,Woody RW.Estimation of protein secondary structure from CD spectra:Inclusion of denatured proteins with native protein in the analysis[J].Anal Biochem,2000,287(2):243-251.
[127]吴瑾光.近代傅里叶变换红外光谱技术及应用(下卷)[M].北京:科学技术文献出版社,1994:192-218.
[128]Byler DM,Susi H.Examination of the secondary structure of proteins by deconvolved FTIR spectra[J].Bioploymers,1986,25(3):469-487.
[129]Byler DM,Bouillette JN,Susi H.Quantitative studies of protein structure by FT-IR spectra deconvolution and curve-fitting[J].Spectroscopy,1986,1(3):29-32.
[130]Pelton,JT,Melean LR,Spectroscopic methods for anaylsis of protein secondary structure[J].Anal Biochem,2000,277:167-176.
[131]Kaiden K,Matsui T,Tanaka S.A study of the amide Ⅲ by FTIR spectrometry of the secondary structure of albumin,myoglobin and γ-globulin[J].Appl Spectrosc,I987,41(2):180-184.
[132]谢孟峡,刘嫒.红外光谱酰胺Ⅲ带用于蛋白质二级结构的测定研究[J].高等学校化学学报,2003,24(2):226-231.
[133]卞为东,孙素琴,黄岳顺,等.FTIR光谱法研究天花粉蛋白的热去折叠过程[J].光谱学与光谱分析,2000,24(4):471-473.
[134]林克椿.医学生物物理学[M].北京:北京大学医学出版社,1999.
[135]汪猷,金善炜.天花粉蛋白(第二版)[M].北京:科学出版社,2000,40-60.
[136]杨频,高飞.生物无机化学原理[M].北京:科学出版社,2002,430-353.
[137]蔡国友,侯玉霞.应用圆二色光谱研究交变应力对烟草细胞膜蛋白结构的影响[J].光子学报,2000,29(4):289-292.
[138]程源,苏静.影响多肽与花粉钙调素亲和性的因素一多肽的圆二色性及核磁共振研究[J].高等学校化学学报,2001,22(5):785-787.
[139]Susi H,Byler DM.Resolution-enhanced Fourier transformation infrared spectroscopy of enzymes[J].Methods Enzymol,1986,130:290-311.
[140]秦身钧,王建滨,姚宏伟,等.计算机辅助解析FTIR定量研究蛋白质构象的用进展[J].河北师范大学学报(自然科学版),2006,30(3):331-335
[141]Bandekar J.Amide modes and protein conformation[J].Biochim Biophys Acta. 1992,1120(2):123-143.
[142]Tuthill CW,Rudolph A,Li Y,et al.Quantitative analysis of thymosin α1 in human serum by LC-MS/MS[J].AAPS Pharm Sci Tech,2000,1:E11
[143]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19:1731-1738.
[144]孙会仙,张淑珍,谢剑炜.蛋白多肽类药物的药代动力学分析方法的研究进展[J].国外医学(药学分册),2006,33(1):63-66.
[145]Gallwitz B,Ropeter T,Morys-Wortmann C,et al.GLP-1-analogues resistant to degradation by dipeptidyl-peptidase Ⅳ in vitro[J].Regul Pept,2000,29,86(1-3):103-111.
[146]Wen JY,Ledger R,McLeod B J,et al.Enzymatic degradation of luteinizing hormone releasing hormone(LHRH) by mucosal homogenates from the intestine of the common brushtail possum(Trichosurus vulpecula)[J].Life Sci,2002,71(25):3019-3030.
[147]Besser D,Muller B,Kleinwachter P,et al.Synthesis and characterization of octapeptide somatostatin analogues with backbone cyclization[J].J Prakt Chem,2000,342(6):537-545.
[148]Amoscato AA,Balasubramaniam A,Alexander JW,et al.Degradation of thymopentin by human lymphocytes:evidence for aminopeptidase activity[J].Biochim Biophys Acta,1988,955:164-174.
[149]Sisto A,Mariotti S,Groggia A,et al.Biologically active retro-inverso analogs of thymopentin[J].Pept Chem Struct Biol Proc Am Pept Symp,1989,11:772-773.
[150]尹雅姝,陈大为,乔明曦,等.RP-HPLC法测定胸腺五肽溶液的稳定性[J].沈阳药科大学学报,2007,24(2):89-93.
[151]刘璐,宋月英,张庆云,等.HPLC法测定胸腺五肽的含量[J].中国药房,2007,18(28):2210-2211.
[152]Kraemer W J,Noble B,Culver B,et al.Changes in plasma proenkephalin peptide F and catecholamine levels during graded exercise in men[J].Proc Natl Acad Sci USA,1985,82(18):6349-6351.
[153]DeGraw JI,Almquist RG,Hiebert CK,et al.Stabilized analogs of thymopentin,1.4,5-ketomethylene pseudopeptides[J].J Med Chem,1997,40:2386-2397.
[154]唐仕炜,袁晓佳,张志荣,等.胸腺五肽三甲基壳聚糖口服纳米粒的研究[J].四川大学学报(医学版),2007,38(5):885-888
[155]Chi Q,Xie X,Zhang J,et al.Synthesis,characterization and biological activities of thymopentin ethyl ester[J].Pharmazie,2008,63(11):784-787.
[156]焦玉焕,孙考祥,慕宏杰,等.胸腺五肽缓释多囊脂质体的制备及大鼠药物代谢动力学的初步研究[J].药学学报,2008,43(7):756-760
[157]Pignatello R,Pecora TM.Conjugmion of thymopentin(TP5)with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity[J].Pharmazie,2007,62(9):663-667.
[158]朱颐申,姚忠,邱芊,等.胸腺五肽肽库制备及其免疫活性分析[J].中国生化药物杂志,2005,26(5):257-260.
[159]DeGraw JI,Almquist RG,Hiebert CK,et al.Stabilized analogs of thymopentin.2.1,2- and 3,4-ketomethylene pseudopeptides[J].J Med Chem,1997,40:2398-2406.
[160]Smith RL,Dousman L,Waud WR,et al.Stabilized analogs of thymopentin.3.valuation of ketomethylene pseudopeptides for antiarthfitic properties[J].J Med Chem,1997,40:2407-2411.
[161]Sharma P,Anuradha,Rohatgi A,et al.Stimulation of nonspecific resistance by thymopentin and its analogs against leishmania donovani infection in hamsters[J].Peptides,1999,20:1381-1383.
[162]余榕捷,高媛,林剑,等.重组环状胸腺五肽结构类似物Cyclo-(Cys-Arg-Lys -Asp-Val-Tyr-)的制备,鉴定和活性检测[J].中国生物化学与分子生物学报,22(8):652-658.
[163]Wieczorek Z,Zimecki M,Trojnar J,et al.Immunomodulatory activity of a potent thymopentin analog:disulphide bridged beta-mercaptopropionyl-arginyl -lysyl-aspartyl-valyl-tyrosyl-cysteine amide[J].Pol J Pharmacol,1996, 48(1):31-38.
[164]Heavner GA,Audhya T,Doyle D,et al.Biologically active conformations of thymopentin.Studies with conformationally restricted analogs[J].Int J Pept Protein Res,1991,37(3):198-209.
[165]Grottesi A,Sette M,Palamara T,et al.The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy.A possible model for its interaction with the lymphocyte membrane[J].Peptides,1998,19:1731-1738.
[166]成静,祝寿芬.三氧化二砷对小鼠免疫系统的影响[J].中国地方病学杂志,2000,1(1):41-43.
[167]曹志然,周文英,陈淑兰,等.十全大补汤对小鼠免疫功能影响的实验研究[J].中国中医基础医学杂志,2000,10(6):34-35.
[168]林学颜,张玲.现代细胞与分子免疫学(第二版)[M].科学出版社,北京:2000.
[169]Denes L,Szende B,Ember J,et al.Immunoregulating peptides Ⅱ.In vitro effects of TP5 analogs on E-rosette formation and cell division[J].Immunopharmaeol Immunotoxicol,1987,9(1):1-18.
[170]John WH.Aspects of the immunopharmacology of thymosin α1[J].Clin Appl Rev,2001,1(3):187-191.
[171]石继红,张英起,赵永同,等.胸腺素α1基因的克隆表达及其生物活性[J].中国生物化学与分子生物学报,2001,17(3):344-349.
[172]Tischio TP,Patrick JE,Weintraub HS,et al.Short in vitro half-life of thymopoietin pentapeptide in human plasma[J],Int J Pept Protein Res,1983,14:479-484.
[173]Kwon KH,Kim KI,Jun WJ,et al.In vitro and in vivo effects of macrophage-stimulatory polysaccharide from leaves of Perilla frutescens var.crispa[J].Biol pharm Bull,2002,25:367-371.
[174]王红梅,马玲,姚小曼.小鼠廓清实验方法比较[J].中国食品卫生杂志,2000,12(3):3-5.
[175]李小定,吴谋成,曾晓波,等.灰树花多糖粗品与纯品的抗肿瘤作用及对免疫功能的影响[J].营养学报,2003,25(1):7-9.
[176]孙翠慈,王安利,王素芬,等.活性多糖对水产动物免疫功能的调节[J].海洋通报,2003,22(3):81-89.